UBS Downgrades Intra-Cellular Therapies to Neutral, Lowers Price Target to $83
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Ashwani Verma has downgraded Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Neutral and lowered the price target from $85 to $83.
June 25, 2024 | 4:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS analyst Ashwani Verma downgraded Intra-Cellular Therapies from Buy to Neutral and lowered the price target from $85 to $83.
The downgrade from Buy to Neutral and the slight reduction in the price target from $85 to $83 by UBS is likely to have a negative short-term impact on ITCI's stock price. Downgrades typically signal reduced confidence in the stock's near-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100